WHAT IS INVASIVE MENINGOCOCCAL DISEASE (IMD)?

A serious and potentially fatal bacterial infection

IMD is a serious bacterial infection caused by the N. meningitidis bacteria, which can lead to dangerous and sometimes fatal diseases including:

  • meningitis (inflammation of the lining of the brain and spinal cord), and
  • sepsis (blood poisoning)
Quick Facts

IMD can be fatal within 24 hours
​​​​​​​of first symptoms.

Even when the disease is treated early, 5% to 10% of patients die, typically within 24-48 hours after symptoms start.

10% to 20% of survivors of meningococcal meningitis can suffer from long-term consequences, such as brain damage, hearing loss or learning disabilities.

Keeping up to date with recommended vaccines is the best defense
against IMD infections

Who is at risk?

After children aged 4 years and under, adolescents and young adults aged 15 to 24 years have the highest rates of reported IMD in Canada.

IMD has historically occurred in:

  • Schools
  • Colleges
  • Camps
  • Other places where there are large groups of teens and young adults

Meningococcal meningitis is
vaccine-preventable
, but…

…routine childhood vaccination programs only cover IMD vaccinations for 4 of the 5 common serogroups:

  • They do not include vaccination for serogroup B

It is up to you to ask your healthcare professional about TRUMENBA

Understanding the different serogroup coverage of meningococcal vaccines

MOST COMMON SEROGROUPS ASSOCIATED WITH IMD

There are 5 serogroups of the N. meningitidis bacteria most commonly associated with IMD: A, C, W135, Y and B.

Serogroup B is the most common cause of IMD in Canadian adolescents and young adults (2013–2017)

Not part of the routine
​​​​​​​Immunization program

TRUMENBA Meningococcal B
vaccine (MenB)

53 % of all reported IMD cases (among identified serogroups) in Canada between 2013 and 2017.

Part of the routine Immunization program

Meningococcal Conjugate C
vaccine (MenC)

4 % of all reported IMD cases (among identified serogroups) in Canada in 2015.

Quadrivalent Meningococcal Conjugate vaccine (MenACWY)
(in most provinces)

30 % of all reported IMD cases (among identified serogroups) in Canada in 2011.

Learn about MenB

A vaccine for meningitis B prevention.

Thank you for signing up for your
TRUMENBA vaccine reminder!